Loomis Sayles & Co. L P Sells 19,679 Shares of Glaukos Co. (NYSE:GKOS)

Loomis Sayles & Co. L P decreased its position in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 2.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 654,072 shares of the medical instruments supplier's stock after selling 19,679 shares during the period. Loomis Sayles & Co. L P owned 1.19% of Glaukos worth $98,072,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. IFP Advisors Inc acquired a new position in shares of Glaukos in the 4th quarter worth approximately $43,000. Asset Planning Inc acquired a new position in Glaukos in the fourth quarter worth approximately $90,000. Picton Mahoney Asset Management acquired a new position in Glaukos in the fourth quarter worth approximately $125,000. Harvest Fund Management Co. Ltd increased its holdings in shares of Glaukos by 2,263.2% in the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier's stock valued at $117,000 after buying an additional 860 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of Glaukos during the 4th quarter valued at $153,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on GKOS. UBS Group initiated coverage on Glaukos in a research report on Friday, December 6th. They set a "buy" rating and a $182.00 target price on the stock. Needham & Company LLC upped their price objective on shares of Glaukos from $149.00 to $176.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Mizuho upgraded shares of Glaukos from a "neutral" rating to an "outperform" rating and raised their target price for the stock from $140.00 to $200.00 in a report on Wednesday, February 19th. Stifel Nicolaus boosted their price target on shares of Glaukos from $153.00 to $175.00 and gave the company a "buy" rating in a report on Tuesday, December 31st. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $180.00 price objective (up previously from $140.00) on shares of Glaukos in a research note on Monday, January 27th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $163.25.

Remove Ads

Insider Activity

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now owns 72,437 shares in the company, valued at $10,658,380.18. This trade represents a 4.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Alex R. Thurman sold 1,520 shares of the business's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the sale, the chief financial officer now owns 53,431 shares of the company's stock, valued at $5,708,568.04. The trade was a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is owned by insiders.

Glaukos Stock Down 4.4 %

GKOS stock traded down $4.45 during mid-day trading on Monday, hitting $97.56. The stock had a trading volume of 254,938 shares, compared to its average volume of 602,105. Glaukos Co. has a 1-year low of $88.16 and a 1-year high of $163.71. The company has a fifty day moving average of $130.52 and a 200 day moving average of $135.78. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $5.52 billion, a price-to-earnings ratio of -34.00 and a beta of 0.99.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). The firm had revenue of $105.50 million during the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. On average, equities analysts expect that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.